AU6298798A - Formulation of stabilized cationic transfection agent(s)/nucleic acid particles - Google Patents

Formulation of stabilized cationic transfection agent(s)/nucleic acid particles

Info

Publication number
AU6298798A
AU6298798A AU62987/98A AU6298798A AU6298798A AU 6298798 A AU6298798 A AU 6298798A AU 62987/98 A AU62987/98 A AU 62987/98A AU 6298798 A AU6298798 A AU 6298798A AU 6298798 A AU6298798 A AU 6298798A
Authority
AU
Australia
Prior art keywords
nucleic acid
transfection agent
formulation
acid particles
cationic transfection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU62987/98A
Other versions
AU737720B2 (en
Inventor
Joel Crouzet
Bruno Pitard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9503492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU6298798(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU6298798A publication Critical patent/AU6298798A/en
Application granted granted Critical
Publication of AU737720B2 publication Critical patent/AU737720B2/en
Assigned to AVENTIS PHARMA S.A. reassignment AVENTIS PHARMA S.A. Amend patent request/document other than specification (104) Assignors: RHONE-POULENC RORER S.A.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Abstract

The invention concerns a composition containing stabilised particles of cationic transfection agent(s)/nucleic acid complexes characterised in that it includes besides said transfection agent and nucleic acid at least a non-ionic surfactant in sufficient amount for preventing the aggregation of the particles in course of time. In a preferred embodiment, the surfactant is a polyoxyalkylene or a derivative thereof.
AU62987/98A 1997-02-10 1998-02-06 Formulation of stabilized cationic transfection agent(s)/nucleic acid particles Ceased AU737720B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9701467A FR2759298B1 (en) 1997-02-10 1997-02-10 FORMULATION OF CATIONIC TRANSFECTING AGENT (S) / NUCLEIC ACID PARTICLES
FR97/01467 1997-02-10
PCT/FR1998/000222 WO1998034648A1 (en) 1997-02-10 1998-02-06 Formulation of stabilised cationic transfection agent(s)/nucleic acid particles

Publications (2)

Publication Number Publication Date
AU6298798A true AU6298798A (en) 1998-08-26
AU737720B2 AU737720B2 (en) 2001-08-30

Family

ID=9503492

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62987/98A Ceased AU737720B2 (en) 1997-02-10 1998-02-06 Formulation of stabilized cationic transfection agent(s)/nucleic acid particles

Country Status (20)

Country Link
EP (1) EP1007097B1 (en)
JP (1) JP2001511171A (en)
KR (1) KR20000070914A (en)
AT (1) ATE206932T1 (en)
AU (1) AU737720B2 (en)
BR (1) BR9807563A (en)
CA (1) CA2278665A1 (en)
CZ (1) CZ282199A3 (en)
DE (1) DE69802102T2 (en)
DK (1) DK1007097T3 (en)
ES (1) ES2166146T3 (en)
FR (1) FR2759298B1 (en)
GR (1) GR3036919T3 (en)
HU (1) HUP0001720A3 (en)
IL (1) IL130765A0 (en)
NO (1) NO993825L (en)
PT (1) PT1007097E (en)
SK (1) SK282685B6 (en)
WO (1) WO1998034648A1 (en)
ZA (1) ZA981034B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
AU768542C (en) * 1998-04-08 2004-06-17 Celltech R & D Limited Lipids
CA2335393C (en) * 1998-07-20 2008-09-23 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
EP1309904A4 (en) * 2000-03-03 2006-03-29 Valentis Inc Improved poloxamer and poloxamine compositions for nucleic acid delivery
GB0009201D0 (en) * 2000-04-14 2000-05-31 Univ Nottingham Cationic polymer - Nucleic acid complexes and methods of making them
US20020091242A1 (en) 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
CA2426582A1 (en) * 2000-10-20 2002-08-08 Valentis, Inc. Gene delivery formulations and methods for treatment of ischemic conditions
EP1232758A1 (en) * 2001-02-19 2002-08-21 Aventis Pasteur Polynucleotide formulated for improved intracellular transfer
WO2005120546A2 (en) * 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2008531732A (en) 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． Compositions and methods for topical application and transdermal delivery of botulinum toxin
JP4653242B1 (en) 2010-02-12 2011-03-16 ナノキャリア株式会社 Particulate pharmaceutical composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
AU5527696A (en) * 1995-03-31 1996-10-16 Children's Hospital Medical Center Use of surfactants for introducing genetic material into lun g cells
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells

Also Published As

Publication number Publication date
DE69802102D1 (en) 2001-11-22
HUP0001720A3 (en) 2001-10-29
BR9807563A (en) 2000-02-01
HUP0001720A1 (en) 2000-09-28
CA2278665A1 (en) 1998-08-13
CZ282199A3 (en) 1999-10-13
SK108299A3 (en) 2000-05-16
ZA981034B (en) 1998-08-11
KR20000070914A (en) 2000-11-25
ES2166146T3 (en) 2002-04-01
DK1007097T3 (en) 2002-02-11
FR2759298A1 (en) 1998-08-14
PT1007097E (en) 2002-04-29
NO993825D0 (en) 1999-08-09
EP1007097A1 (en) 2000-06-14
GR3036919T3 (en) 2002-01-31
JP2001511171A (en) 2001-08-07
WO1998034648A1 (en) 1998-08-13
ATE206932T1 (en) 2001-11-15
DE69802102T2 (en) 2002-03-14
IL130765A0 (en) 2001-01-28
NO993825L (en) 1999-08-09
EP1007097B1 (en) 2001-10-17
SK282685B6 (en) 2002-11-06
FR2759298B1 (en) 1999-04-09
AU737720B2 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
AU6298798A (en) Formulation of stabilized cationic transfection agent(s)/nucleic acid particles
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
EP0911039A3 (en) Drug-resin complexes stabilized by chelating agents
HK1017995A1 (en) Compounds and compositions for delivering active agents.
AU3924895A (en) Pharmaceutical compositions
HK1028548A1 (en) Formulations for hydrophobic pharmaceutical agents
IL172835A0 (en) A composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids
BR9906916A (en) Powder coating composition
WO2000032186A3 (en) Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
CA2194979A1 (en) Solid drug forms containing clathrates of steroid sex hormones
WO2000050046A8 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
YU8701A (en) New oral formulation
WO2000072820A3 (en) Injectable anesthetic formulation
AU1869601A (en) Pharmaceutical compositions comprising trimegestone
AU7049296A (en) Stabilization of non-halogenated 3-isothiazolones in aggressive systems
RO117500B1 (en) Cosmetic composition
CA2295703A1 (en) Cosmetic composition comprising an amide and novel amides
WO2004058186A3 (en) Formulations for pulmonary delivery
WO2002017956A3 (en) Stabilized fgf formulations containing reducing agents
WO1998023260A3 (en) Non-ionic surfactant vesicles as a delivery agent for nucleic acid
WO2001006963A3 (en) Orthopaedic bone cement mixing container
EP0891778A3 (en) Agents for the prevention and/or treatment of radiation-induced disorders
HU9700244D0 (en) 3-[1-phenyl-3-(4'-halogenide-biphenyl-4-yl)-3-3-oxo-or hydroxipropile]-4-acyloxi-cumarine derivatives and rodenticide compositions containing these compounds as active ingredients, and preparation thereof

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: AVENTIS PHARMA S.A.

Free format text: FORMER NAME: RHONE-POULENC RORER S.A.

FGA Letters patent sealed or granted (standard patent)